Macroprolactinemia: New insights in hyperprolactinemia;Makroprolaktinemija: Novi uvidi u hiperprolaktinemiji

Biochemia Medica

Volumn 22, Issue 2, 2012, Pages 171-179

  Kasum, Miro ^a   Oreskovic, Slavko ^a   Zec, Ivana ^b   Jezek, Davor ^b,c   Tomic, Vlatka ^b,c   Gall, Vesna ^b,c   Adzic, Goran ^d  

^a KBC Zagreb   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d UNIVERSITY OF MOSTAR   (Bosnia and Herzegovina)

Author keywords

Clinical features; Diagnosis; Macroprolactin; Pathophysiology

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN; MACROGOL; PROLACTIN; MACROGOL DERIVATIVE; PROLACTIN, POLYMERIC;

ANTIGENICITY; CLINICAL FEATURE; GEL FILTRATION CHROMATOGRAPHY; HUMAN; HYPERPROLACTINEMIA; LABORATORY DIAGNOSIS; MACROPROLACTINEMIA; PATHOPHYSIOLOGY; POPULATION RECOVERY; PRECIPITATION; PREVALENCE; REVIEW; BLOOD; CHEMISTRY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; GEL CHROMATOGRAPHY; HYPOPHYSIS; METABOLISM; METHODOLOGY; MOLECULAR WEIGHT; PROLACTINOMA;

CHROMATOGRAPHY, GEL; CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC ERRORS; HUMANS; HYPERPROLACTINEMIA; MOLECULAR WEIGHT; PITUITARY GLAND; POLYETHYLENE GLYCOLS; PROLACTIN; PROLACTINOMA;

EID: 84866841997     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/bm.2012.020     Document Type: Review

References (50)

1. Yen SSC. Prolactin in human reproduction. In: Yen SSC, Jaffe RB, eds. Reproductive endocrinology. Philadephia: WB Saunders company; 1986. p. 237-63.
2. Glezer A, Soares CR, Vieira JG, Giannella-Neto D, Ribela MT, Goffin V, Bronstein MD. Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. J Clin Endocrinol Metab 2006;91:1048-55.
3. Cárdenas-Mondragón G, Ulloa-Aguirre A, Isordia-Salas I, Goffin V, Leaños-Miranda A. Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays. J Rheumatol 2007;34:1514-21.
4. Sluijmer AV, Lapohohn RE. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril 1992;58:72-7.
5. Speroff L. Amenorrhea. In: Speroff RH, Kase NG, eds. Clinical Gynecological Endocrinology and Infertility. Baltimore: Williams and Wilkins; 1989. p. 165-211.
6. Lindstedt G. Endogenous antibodies against prolactin: a "new" cause of hyperprolactinemia. Eur J Endocrinol 1994;130:429-32.
7. Hattori N. Macroprolactinemia: a new cause of hyperprolactinemia. J Pharmacol Sci 2003;92:171-7.
8. Donadio F, Barbieri A, Angioni R, Mantovani G, Beck-Peccoz P, Spada A, Lania AG. Patients with macroprolactinaemia: clinical and radiological features. Eur J Clin Invest 2007;37:552-7.
9. de Soarez PC, Souza SC, Vieira JG Ferraz MB. The effect of identifying macroprolactinemia on health-care utilization and costs in patients with elevated serum prolactin levels. Value Health 2009;12:930-4.
10. Whittaker PG, Wicox T, Lind T. Maintained fertility in a patient with hyperprolactinemia due to big-big prolactin. J Clin Endocrinol Metab 1981;53:863-6.
11. Anderson AN, Pedersen H, Djursing H, Andersen BJ, Friesen HG. Bioactivity of prolactin in a woman with an excess of large molecular size prolactin, persistent hyperprolactinemia and spontaneous conception. Fertil Steril 1982;38:625-8.
12. Jackson RD, Wortsman J, Malarkey WB. Macroprolactinemia presenting like a pituitary tumor. Am J Med 1985;78:346-50.
13. Bjoro T, Makrid L, Wergerland R, Turter A, Kvistborg A, Sand T. Frequency of hyperprolactinemia due to large molecular weight prolactin (150-170 kD PRL) Scand J Clin Lab Invest 1995;55:139-47.
14. Hattori N, Ishihara T, Saiki Y. Macroprolactinemia prevalence and aetilogies in a large group of hospital workers. Clin Endocrinol (Oxf) 2009;71:702-8.
15. Fahie-Wilson MN, Soule SG. Macroprolactinemia contribution to hyperprolactinemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem 1997;34:252-8.
16. Suliman AM, Smith TP, Gibney J, McKenna TJ. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening application of a new strict laboratory definition of macroprolactinemia. Clin Chem 2003;49:1504-9.
17. Hauache OM, Rocha AJ, Maia AC, Maciel RM, Vieira JG. Screening for macroprolactinemia and pituitary imaging studies. Clin Endocrinol (Oxf) 2002;57:327-31.
18. Bonhoff A, Vuille JC, Gomez F, Gellersen B. identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable-IgG complex. Exp Clin Endocrinol Diabetes 1995;103:252-5.
19. Coudevylle N, Rokas D, Sakarellos-Daitsiotis M, Krikorian D, Panou-Pomonis E, Sakarellos C, et al. Phosphorylated and nonphosphorylated epitopes of the La/SSB autoantigen: comparison of their antigenic and conformational characteristics. Biopolymers 2006;84:368-82.
20. Hattori N, Ikekubo K, Nakaya Y, Kitagawa K, Inagaki C. Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. J Clin Endocrinol Metab 2005;90:3036-44.
21. Hattori N, Nakayama N, Kitagawa K, Li T, Inagaki C. Development of anti-PRL (Prolactin) autoantibodies by homologous PRL in rats: a model for macroprolactinemia. Endocrinology 2007;148:2465-70.
22. De Marinis L, Mancini A, Minnielli S, Masala R, Anile C, Maira G, Barbarino A. Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients. Metabolism 1985;34:917-22.
23. Hattori N, Nakayama Y, Kitagawa K, Ishihara T, Saiki Y, Inagaki C. Anti-prolactin (PRL) autoantibody binding sites (epitopes) on PRL molecule in macroprolactinemia. J Endocrinol 2006;190:287-93.
24. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002;87:581-8.
25. Vilar L, Naves LA, Freitas MC, Lima M, Canadas V, Albuquerque JL, et al. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia. Minerva Endocrinol 2007;32:79-86.
26. Olukoga AO. Macroprolactinemia is clinically important. J Clin Endocrinol Metab 2002;87:4833-4.
27. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 2005;90:3927-32.
28. Can M, Guven B, Atmaca H, Acikgoz S, Mungan G. Clinical characterization of patients with macroprolactinemia and monomeric hyperprolactinemia. Kaohsiung J Med Sci 2011;27:173-6.
29. Tamer G, Telci A, Mert M, Uzum AK, Aral F, Tanakol R. Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine 2012;41:138-43.
30. Chalal J, Schlechte J. Hyperprolactinemia. Pituitary 2008;11:141-6.
31. Hong JW, Lee MK, Kim SH, Lee EJ. Discrimination of prolactinoma from hyperprolactinemic nonfunctioning adenoma. Endocrine 2010;37:140-7.
32. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Janet A, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011;96:273-88.
33. Koch L. New Endocrine Society guideliness for hyperprolactinemia piecing together the pituitary puzzle. Nat Rev Endocrinol 2011;7:247.
34. Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol 2005;62:633-43.
35. Gilson G, Schmit P, Thix J, Hoffman JP, Humbel RL. Prolactin results for samples containing macroprolactin are method and sample dependent. Clin Chem 2001;47:331-3.
36. Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big-big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 2002;87:5410-5.
37. Dodig S. Interferences in quantitative immunochemical methods. Biochem Med 2009;19:50-62.
38. Fahie-Wilson MN. Detection of macroprolactin causing hyperprolactinemia in commercial assays for prolactin. Clin Chem 2000;46:2023-4.
39. Kavanagh L, McKenna TJ, Fahie-Wilson MN, Gibney J, Smith TP. specificity and clinical utility of methods for the detection of macroprolactin. Clin Chem 2006;52:1366-72.
40. Smith TP, Gibney J, Kavanagh L, Fahie-Wilson M, McKenna TJ. specificity and clinical utility of methods for the detection of macroprolactin. Irish J Med Sci 2003;172(Suppl.1):15-6.
41. Quinn AM, Rubinas TC, Garbincius CJ, Holmes EW. Determination of ultrafilterable prolactin: Elimination of macroprolactin interference with a monomeric prolactin-selective sample pretreatment. Arch Pathol Lab Med 2006;130:1807-12.
42. Beda-Maluga K, Pisarek H, Komorowski J, Pawlikowski M, Świe{ogonek}tosławski J, Winczyk K. The detection of macroprolactin by precipitation and ultrafiltration methods. Endokrynol Pol 2011;62:529-36.
43. Fahie-Wilson M, Brunsden P, Surrey J, Everitt A. Macroprolactin and the Roche Elecsys prolactin assay: characteristics of the reaction and detection by precipitation with polyethylene glycol. Clin Chem 2000;46:1993-5.
44. Espinoza JR, Trigos-Landa A, Bocanegra-Garcia V, Acosta-González RI, Bocanegra-Alonso A, Rivera-Sánchez G. Assessment of macroprolactin after polyethylene glycol precipitation in two commercial Immunoassay. Bioquimia 2006;31:140-5.
45. Beltran L, Fahie-Wilson MN, McKenna TJ, Kavanagh L, Smith TP. Serum Total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms. Clin Chem 2008;54:1673-81.
46. McCudden CR, Sharpless JR, Grenache DG. Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin. Clin Chim Acta 2010;411:155-60.
47. Leslie H, Courtney CH, Bell PM, Hadden DR, McCance DR, Ellis PK, et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 2001;86:2743-6.
48. Fahie-Wilson M, Halsall D. Polyethylene glycol precipitation: proceed with care. Ann Clin Biochem 2008;45:233-5.
49. WHO International Standard Prolactin, Human. NIBSC code: 84/500 Instructions for use (Version 3.0, Dated 10/12/2007) Available at: http://www.nibsc.ac.uk/documents/ ifu/84-500.pdf. Accessed March 8, 2012.
50. Sonntag O. Quality in the analytical phase. Biochem Med 2010;20:147-53.